Abstract: A battery management device to be mounted on an electric vehicle including a driving wheel, a traveling motor configured to generate a driving force for the driving wheel, and a battery configured to store electric power to be consumed by the traveling motor. The battery management device includes a detector configured to detect a state of the battery, and a controller configured to calculate a characteristic value indicating performance of the battery based on an output of the detector, and manage charging and discharging of the battery based on the characteristic value. The controller is configured to, when the characteristic value has deterioration, determine whether the deterioration of the characteristic value is reversible deterioration based on the output of the detector. The controller is configured to, upon determining that the deterioration of the characteristic value is the reversible deterioration, return the characteristic value to a value before the deterioration.

Abstract: The present invention provides a compound represented by formula (I): wherein the dashed line indicates the presence or absence of a bond; R1 is carboxy or the like; L is substituted or unsubstituted non-aromatic carbocyclyldiyl or the like; R2 is substituted or unsubstituted alkyl; R3 is a hydrogen atom or the like; X is ?CRX— or ?N—; Y is ?CRY— or ?N—; U is —CRU? or —N?; V is —CRV? or —N?; W is ?CRW— or ?N—; ZA is —C? or —N—; ZB is —CR5R6— or the like; ZC is —CR7R8— or the like; RX, RY, RV and RW are each independently a hydrogen atom or the like; RU is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; R7 and R8 are each independently a hydrogen atom or the like; R4 is substituted or unsubstituted alkyloxy or the like, or a pharmaceutically acceptable salt thereof, having an antiviral activity; and a pharmaceutical composition comprising the same.

Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.

Abstract: An organic electroluminescence element including an anode, a light-emitting layer, a functional layer, and a cathode stacked in this order. The light-emitting layer and the functional layer are in contact with each other. Hole mobility of the light-emitting layer is greater than electron mobility of the light-emitting layer. The electron mobility of the light-emitting layer is equal to or greater than an effective electron mobility of the functional layer. A highest occupied molecular orbital (HOMO) level of a first functional material included in the light-emitting layer is at least 0.4 eV greater than a HOMO level of a second functional material included in the functional layer.

Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; R1 is fluorine; m is any integer of 1 to 2; and n is any integer of 1 to 2.

Abstract: An organic EL element including an anode, a cathode, and a light emitting layer between the anode and the cathode. The light emitting layer includes a fluorescent material and a host material. A difference between a lowest unoccupied molecular orbital (LUMO) level of the fluorescent material and a highest occupied molecular orbital (HOMO) level of the fluorescent material is less than or equal to a difference between a LUMO level and a HOMO level of the host material. The LUMO level of the fluorescent material is equal to or higher than the LUMO level of the host material. The HOMO level of the fluorescent material is equal to or higher than the HOMO level of the host material, and a difference in energy level between the HOMO level of the fluorescent material and the HOMO level of the host material is 0.3 eV or less.

Abstract: An organic EL element including an anode, a first functional layer including organic material, disposed above the anode, a second functional layer including organic material, disposed on and in contact with the first functional layer, a light emitting layer disposed on and in contact with the second functional layer, and a cathode disposed above the light emitting layer. A highest occupied molecular orbital (HOMO) level of the organic material of the second functional layer has an energy level at least 0.2 eV lower than that of a HOMO level of the organic material of the first functional layer, and film thickness of the second functional layer is 15 nm or less.

Abstract: An organic electroluminescence element including an anode, a light-emitting layer, a functional layer, and a cathode stacked in this order. The light-emitting layer and the functional layer are in contact with each other. Hole mobility of the light-emitting layer is greater than electron mobility of the light-emitting layer. The electron mobility of the light-emitting layer is equal to or greater than an effective electron mobility of the functional layer. A highest occupied molecular orbital (HOMO) level of a first functional material included in the light-emitting layer is at least 0.4 eV greater than a HOMO level of a second functional material included in the functional layer.

Abstract: The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3AR3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

Abstract: Disclosed is a light-emitting layer-forming ink useful in forming an organic light-emitting layer for an organic EL element by a printing process, including a tetralin-based organic solvent, and a solute including an anthracene-based, low molecular material and dissolved at a concentration of 3% or higher and 12% or lower in the tetralin-based organic solvent.

Abstract: Provided is an organic electroluminescent element obtained by stacking an anode, a light emitting layer, an electron transport layer, and a cathode in that order, the organic electroluminescent element including an electron injection control layer in contact with both the light emitting layer and the electron transport layer, in which the light emitting layer contains a fluorescent material as a luminescent material, a lowest unoccupied molecular orbital level of a functional material contained in the electron injection control layer is higher than a lowest unoccupied molecular orbital level of a functional material contained in the electron transport layer by 0.1 eV or higher, and the lowest unoccupied molecular orbital level of the functional material contained in the electron injection control layer is equal to or higher than a lowest unoccupied molecular orbital level of a functional material contained in the light emitting layer.

Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.

Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.

Abstract: An organic electroluminescence (EL) element including: an anode; a first functional layer above the anode, the first functional layer having at least one of a hole injection property and a hole transport property; a light-emitting layer above the first functional layer, the light-emitting layer including an organic light-emitting material doped with an electron donor material; a second functional layer above the light-emitting layer, the second functional layer having at least one of an electron injection property and an electron transport property; and a cathode disposed above the second functional layer, wherein carrier density of the light-emitting layer is from 1012/cm3 to 1019/cm3.

Abstract: The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3AR3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

Abstract: The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3AR3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

Abstract: The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3-hydroxy-4-pyridone derivative prodrug having cap-dependent endonuclease inhibitory activity.

Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.

Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.